EGFRIs相关性皮肤不良反应研究进展

Research Progress on EGFRIs Related Adverse Skin Reactions

表皮生长因子受体抑制剂(epidermal growth factor receptor inhibitors,EGFRIs)是目前肿瘤领域应用最广泛的分子靶向治疗药物,其代表药物包括吉非替尼、厄洛替尼和埃克替尼等。在EGFRIs取得疗效的同时,其给患者带来的皮肤不良反应也不容忽视,严重时可影响肿瘤患者的用药剂量,甚至中断治疗。本研究主要对EGFRIs引起皮肤不良反应的临床表现与发生机制进行综述,包括对角质形成细胞的增殖、凋亡、分化的影响,激活炎症反应及增加皮肤光敏性,为减轻药物不良反应,提高患者用药依从性,从而为提高肿瘤疗效提供新的治疗思路。

The human epidermal growth factor receptor inhibitors(EGFRIs)are the most widely used molecular targeted therapy drugs in cancer field at present.The representative drugs includes gifetinib,erlotinib,and ectatinib.While EGFRIs achieve efficacy,the adverse skin reactions brought to the patients by them can not be ignored.In severe cases,they can affect the dose of cancer patients and even interrupt treatment.This paper reviews the clinical manifestation and mechanism of adverse skin reactions caused by EGFRIs,including alterations of keratinocyte proliferation,differentiation and apoptosis,enhanced inflammatory response and photosensitivity to ultraviolet radiation.It is expected that these mechanism studies will provide new treatment ideas to reduce the adverse drug reaction,improve the patient drug compliance and improve the efficacy on tumor.